Focal Segmental Glomerulosclerosis Market

Global Focal Segmental Glomerulosclerosis Market Size, Share and Trends Analysis Report, By Disease Type (Primary FSGS and Secondary FSGS), By Disease Management (Diagnosis (Kidney Biopsy, Creatinine Test, and Other Diagnosis), By Treatment (Drug Therapy, Dialysis, and Kidney Transplant)), Forecast (2021-2027)
    Update Available - Forecast 2024-2030   

Published: Jul 2023 | Report Code: OMR2025973 | Category : Pharmaceuticals | Delivery Format: /

The global focal segmental glomerulosclerosis (FSGS) market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market include the increasing prevalence of FSGS, rising focus towards rare diseases, and increasing R&D activity. Moreover, in both developed and emerging markets, increasing demand for the kidney transplants and a higher rate of hospitalizations have been witnessed, due to kidney malfunction. This increases the demand for diagnosis of the initial stage of FSGS diseases during the treatment of kidney diseases. Thus, the burden of glomerulus-related disorders drives the global FSGS market during the forecast period. FSGS is the progressive scarring of the kidney, which is characterized by proteinuria. It is among the rare diseases, which affects kidney function by attacking and damaging the glomeruli. This disease is characterized by kidney defects by birth, obesity, obstructive sleep apnea, sickle cell anemia, viruses, such as HIV, among others. 

Primary FSGS has become one of the most common causes of idiopathic glomerular disease in adults. The primary FSGS is usually idiopathic, which refers to the rise of disease without any known, definite or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults. The current therapy for the primary FSGS includes immunosuppressive agents, such as glucocorticoids and calcineurin inhibitors. Steroid therapy is among the most basic and standard treatment with oral prednisone. Some of the emerging companies having their potential drug candidates in the pipeline which include Chemocentryx, Reata, Pharmaceuticals, Retrophin Inc., and Vertex Pharmaceuticals. Since it is a rare disease, specialty clinical-stage companies are likely to get more funds that can leverage the strategic partnership opportunities. Moreover, the companies are directing their R&D efforts toward more targeted therapies as a solution to traditional drug and surgical treatments, which in turn, is expected to fuel the growth of the global focal segmental glomerulosclerosis market.

Market Coverage

The market number available for – 2020-2027

Base year- 2020

Forecast period- 2021-2027

Segment Covered- 

o By Disease Type 

o By Disease Management

o By Treatment 

Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape: Novartis International AG, Variant Pharmaceuticals, Inc., and AbbVie Inc., among others. 

Key questions addressed by the report

What is the market growth rate?

Which segment and region dominate the market in the base year?

Which segment and region will project the fastest growth in the market?

How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?

How are players addressing challenges to sustain growth?

Where is the investment opportunity?

Global Focal Segmental Glomerulosclerosis Market Report by Segment

By Disease Type

Primary FSGS

Secondary FSGS

By Disease Management

Diagnosis

o Kidney Biopsy

o Creatinine Test

o Other Diagnosis

Treatment

o Drug Therapy

o Dialysis

o Kidney Transplant

Global Focal Segmental Glomerulosclerosis Market Report by Region

North America       

US

Canada

Europe

Germany

UK

France

Spain

Italy

Rest of Europe

Asia-Pacific    

China

Japan

India

Rest of Asia-Pacific

Rest of the World

Latin America

Middle East and Africa